A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. Our products and technology, which include our HiFi long-read sequencing technology, address a broad set of applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Our focus is on creating some of the world's most advanced sequencing systems to provide our customers with the most complete and accurate view of genomes, transcriptomes, and epigenomes.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | 201M | - | 131M |
| Net Income | -546M | -546M | -310M | -307M | -314M | -181M |
| EPS | $-1.82 | $-1.82 | $-1.59 | $-1.21 | $-1.40 | $-0.89 |
| Free Cash Flow | -114M | -114M | -212M | -268M | -280M | -117M |
| ROIC | -74.5% | -84.0% | -26.8% | -19.2% | -21.5% | -10.7% |
| Gross Margin | - | - | - | 26.3% | - | 45.1% |
| Debt/Equity | 120.65 | 120.65 | 1.28 | 1.27 | 1.60 | 1.13 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -554M | -554M | -474M | -334M | -307M | -210M |
| Operating Margin | 0.0% | - | - | -166.8% | - | -161.2% |
| ROE | -10214.5% | -213.5% | -61.2% | -43.7% | -55.8% | -22.9% |
| Shares Outstanding | 300M | 300M | 195M | 254M | 224M | 204M |
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 35.7%.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) has a 5-year average return on invested capital (ROIC) of -32.5%. This is below average and may indicate limited pricing power.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) has a market capitalization of $435M. It is classified as a small-cap stock.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) does not currently pay a regular dividend.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) operates in the Laboratory Analytical Instruments industry, within the Technology sector.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) generated $-114 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) has a debt-to-equity ratio of 120.65. This indicates higher leverage, which may increase financial risk.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) reported earnings per share (EPS) of $-1.82 in its most recent fiscal year.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) has a return on equity (ROE) of -213.5%. A negative ROE may indicate losses or negative equity.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) has a 5-year average gross margin of 35.7%. This indicates decent pricing power.
The Ledger Terminal provides 16 years of financial data for PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) has a book value per share of $0.02, based on its most recent annual SEC filing.